I-Psychopharmacology (Berl). I-2015 Jun 20.
UJanssen LK1, Sescousse G, UHashemi MM, Isibalixesha MH, Ter Huurne NP, Geurts DE, Ukupholisa R.
Abstract
INDLELA YOKUZIPHATHA:
Ukungcakaza kwePathological kuye kwanxulunyaniswa nokungahambi kakuhle kokuhanjiswa kwe-dopamine, ngakumbi ukunqongophala kwe-dopamine D2-receptor, kunye nokusilela ekufundeni. Ngapha koko, ii-akhawunti zethiyori ezixhaphakileyo zibonisa indima ephambili ye-dopamine ekufundeni okubuyela umva. Nangona kunjalo, abukho ubungqina obubambekayo bonxibelelwano oluthe ngqo phakathi kwe-dopamine, ukufunda okubuyela umva kunye nokungcakaza kwe-pathological.
INJONGO:
Injongo yolu phononongo kukwenza unxantathu we-dopamine, ukubuyisela umva ukufunda, kunye nokungcakaza kwe-pathological.
IINDLELA:
Apha, sivavanya i-hypothesis yokuba ukungcakaza kwe-pathological kukhatshwa ziingxaki ezinxulumene ne-dopamine ngokufunda kumvuzo kunye nesohlwayo ngokuphanda iziphumo ze-dopamine D2-receptor antagonist sulpiride (400 mg) kumvuzo- kunye nokufunda okubuyela umva kwisohlwayo kwi-18 yokungcakaza kwezifo. kunye ne-22 yokulawula okunempilo, usebenzisa i-placebo-elawulwayo, i-double-blind, i-counter-balanced design.
IINKCUKACHA:
Ngokuhambelana nezifundo zangaphambili, ibhlokhi yee-receptors ze-D2 ezinomvuzo ophazamisekileyo we-sulpiride ngokuchasene nokufunda kokubuyisela umva isohlwayo kulawulo. Ngokwahlukileyo koko, i-sulpiride yayingenazo naziphi na iziphumo ezingqalileyo kubangcakazi.
UKUQINISWA:
Ezi datha zibonisa ukuba ungcakazo lwe-pathological lunxulunyaniswa ne-dopamine-enxulumene ne-anomaly ekubuyiseleni umva kokufunda kumvuzo kunye nesohlwayo.
;